Related Experiment Videos
Expansion of repetitive DNA into cytogenetically visible elements
N Serakinci1, B Pedersen, J Koch
1Department of Cytogenetics, Danish Cancer Society, Aarhus C, Denmark.
Cytogenetics and Cell Genetics
|July 4, 2001
Summary
Amplified repetitive DNA elements, normally invisible, became visible in cancer samples. Molecular analysis corrected initial diagnoses, revealing amplified D1Z2 repeats and an unidentified AT-rich DNA element at chromosome 22 tip.
Area of Science:
- Genetics and Genomics
- Cancer Research
- Molecular Cytogenetics
Background:
- Traditional cytogenetic methods like chromosome banding may miss subtle alterations in repetitive DNA.
- Repetitive elements play crucial roles in genome stability and can be involved in cancer development.
- Accurate identification of chromosomal abnormalities is vital for cancer diagnosis and prognosis.
Observation:
- Two cancer cases presented with cytogenetically visible amplified repetitive DNA elements not typically detected by standard banding.
- Case 1: An initial diagnosis of an addition to chromosome 1 short arm was revised to D1Z2 repeat amplification.
- Case 2: A DAPI-positive band at chromosome 22 short arm tip, initially diagnosed as add(22), contained telomeric repeats internally but lacked them distally.
Findings:
- Molecular analysis successfully identified amplified D1Z2 repeats in the first case, correcting the cytogenetic diagnosis.
- The second case revealed an unidentified, AT-rich repetitive DNA element at the chromosome 22 telomere, possibly due to translocation and expansion.
- The precise identity of the amplified element in the second case remains elusive despite various molecular probes and hybridization techniques.
Implications:
- Highlights the utility of molecular techniques in refining diagnoses of chromosomal abnormalities involving repetitive DNA in cancer.
- Suggests that amplified repetitive elements, even those of unknown origin, can manifest as cytogenetic abnormalities in malignancy.
- Underscores the need for advanced molecular cytogenetic approaches to fully characterize complex genomic alterations in cancer.